Dr. Patel co-authored two papers linking the antimalarial drug hydroxychloroquine to higher mortality rates in COVID-19 patients in The Lancet and the New England Journal of Medicine. The papers drew widespread concern, causing the World Health Organization to suspend its clinical trial on hydroxychloroquine to further examine the drug’s safety. Both journals retracted the papers June 4 after questions of accuracy arose surrounding the papers’ data source, analytics company Surgisphere.
Dr. Patel’s affiliation with the university was listed on both of the retracted papers. A spokesperson declined to comment on the motivation behind the university’s decision, telling STAT, “The University of Utah does not comment on reasons surrounding termination of academic appointments.”
More articles on pharmacy:
Remdesivir could make billions for Gilead, analyst says
FDA’s vaccine head quits Operation Warp Speed days after joining
Drug wholesale, net prices increasing at slower rate, study says
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
